focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.60
Bid: 0.55
Ask: 0.65
Change: 0.00 (0.00%)
Spread: 0.10 (18.182%)
Open: 0.60
High: 0.00
Low: 0.00
Prev. Close: 0.60
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Schedule 1 - Provexis plc

6 Jun 2005 17:05

AIM06 June 2005 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME:Provexis plc COMPANY ADDRESS:10 Williams House Manchester Science Park Lloyd Street North Greater Manchester COMPANY POSTCODE:M15 6SE COUNTRY OF INCORPORATION:England and Wales COMPANY BUSINESS:Nutraceutical company which develops scientifically proven, proprietary, functional foods, supplements andmedical foods DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to whichit seeks admission and the number and type to be held as treasury shares):249,628,324 ordinary shares of 1p each comprising: 33,218,388 shares (Capital reorganisation of Existing Shares) 67,424,000 shares (Placing) 111,658,555 shares (Vendor consideration) 37,327,381 shares (Loans conversion) CAPITAL TO BE RAISED ON ADMISSION:£3.8 million FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Dawson Buck (Non-executive Chairman) Neville Bain (Non-executive Deputy Chairman) Stephen Franklin (Chief Executive) Stephen Moon (Commercial Director) PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUEDSHARE CAPITAL BEFORE ADMISSION: Number of ordinary Percentage of issued shares share capitalRising Stars Growth Fund 58,959,444 23.62Progeny BioVentures Limited 31,969,179 12.81ANGLE Technology Limited 29,926,464 11.99North West Equity Fund 13,514,990 5.41Rowett Research Services Limited 13,167,873 5.28 NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (G) OFTHE AIM RULES:None ANTICIPATED ACCOUNTING REFERENCE DATE:31 March EXPECTED ADMISSION DATE:23 June 2005 NAME AND ADDRESS OF NOMINATED ADVISER:Arbuthnot Securities Limited Arbuthnot House 20 Ropemaker Street London EC2Y 9AR NAME AND ADDRESS OF BROKER:Arbuthnot Securities Limited Arbuthnot House 20 Ropemaker Street London EC2Y 9AR DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH ASTATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITSSECURITIES:Arbuthnot Securities Limited Arbuthnot House 20 Ropemaker Street London EC2Y 9AR The Admission document contains full details about the applicant and the admission of itssecurities. DATE OF NOTIFICATION:6 June 2005 NEW/ UPDATE (see note):New QUOTED APPLICANTS MUST ALSO COMPLETE THE FOLLOWING:N/ATHE NAME OF THE AIM DESIGNATED MARKET UPON WHICH THE APPLICANT'S SECURITIES HAVE BEEN TRADED: THE DATE FROM WHICH THE APPLICANT'S SECURITIES HAVE BEEN SO TRADED: CONFIRMATION THAT, FOLLOWING DUE AND CAREFUL ENQUIRY, THE APPLICANT HAS ADHERED TO ANY LEGAL AND REGULATORYREQUIREMENTS INVOLVED IN HAVING ITS SECURITIES TRADED UPON SUCH A MARKET: AN ADDRESS OR WEB-SITE ADDRESS WHERE ANY DOCUMENTS OR ANNOUNCEMENTS WHICH THE APPLICANT HAS MADE PUBLIC OVER THELAST TWO YEARS (IN CONSEQUENCE OF HAVING ITS SECURITIES SO TRADED) ARE AVAILABLE: DETAILS OF THE APPLICANT'S STRATEGY FOLLOWING ADMISSION INCLUDING, IN THE CASE OF AN INVESTING COMPANY, DETAILSOF ITS INVESTMENT STRATEGY: A DESCRIPTION OF ANY SIGNIFICANT CHANGE IN FINANCIAL OR TRADING POSITION OF THE APPLICANT, WHICH HAS OCCURREDSINCE THE END OF THE LAST FINANCIAL PERIOD FOR WHICH AUDITED STATEMENTS HAVE BEEN PUBLISHED: A STATEMENT THAT THE DIRECTORS OF THE APPLICANT HAVE NO REASON TO BELIEVE THAT THE WORKING CAPITAL AVAILIABLE TOIT OF ITS GROUP WILL BE INSUFFICIENT FOR AT LEAST TWELVE MONTHS FROM THE DATE OF ITS ADMISSION: DETAILS OF ANY LOCK-IN ARRANGEMENTS PURSUANT TO RULE 7 OF THE AIM RULES: A BRIEF DESCRIPTION OF THE ARRANGEMENTS FOR SETTLING THE APPLICANT'S SECURITIES: A WEBSITE ADDRESS DETAILING THE RIGHTS ATTACHING TO THE APPLICANT'S SECURITIES: INFORMATION EQUIVALENT TO THAT REQUIRED FOR AN ADMISSION DOCUMENT WHICH IS NOT CURRENTLY PUBLIC: A WEBSITE ADDRESS OF A PAGE CONTAINING THE APPLICANT'S LATEST ANNUAL REPORT AND ACCOUNTS WHICH MUST HAVE AFINANCIAL YEAR END NOT MORE THEN NINE MONTHS PRIOR TO ADMISSION. THE ACCOUNTS MUST BE PREPARED ACCORDING TO UKOR US GAAP OR INTERNATIONAL ACCOUNTING STANDARDS. THE NUMBER OF EACH CLASS OF SECURITIES HELD IN TRESURY. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th Oct 20094:35 pmRNSPrice Monitoring Extension
20th Oct 20097:00 amRNSChange of Adviser
15th Oct 200910:46 amRNSResult of General Meeting
12th Oct 20097:00 amRNSProvexis Announces Update on Human Trial
7th Oct 20094:36 pmRNSHolding(s) in Company
2nd Oct 20091:09 pmRNSHolding(s) in Company
29th Sep 200910:00 amRNSPosting of Circular
28th Sep 20092:40 pmRNSHolding(s) in Company
25th Sep 20097:00 amRNSSubscription and Notice of General Meeting
23rd Sep 20099:54 amRNSShare Price Movement
17th Sep 20092:15 pmRNSDirectorate Change
10th Sep 20093:10 pmRNSResult of AGM
8th Sep 200912:33 pmRNSAdditional Listing
3rd Sep 20094:12 pmRNSAdditional Listing
3rd Sep 200912:37 pmRNSHolding(s) in Company
28th Aug 20098:53 amRNSRecent share price increase
26th Aug 20093:08 pmRNSDisposal of Provexis Holding
25th Aug 200910:32 amRNSHolding(s) in Company
25th Aug 200910:27 amRNSHolding(s) in Company
17th Aug 20099:25 amRNSAnnual Financial Report
11th Aug 20094:22 pmRNSHolding(s) in Company
11th Aug 20097:00 amRNSCommencement of Clinical Trial
10th Aug 20099:43 amRNSRecent share price movement
2nd Jul 20094:44 pmRNSHolding(s) in Company
9th Jun 20097:00 amRNSAudited Results Year ended 31 March 2009
28th May 20097:00 amRNSEuropean Health Claim Adoption for Fruitflow
4th Feb 20097:00 amRNSSirco Launch
3rd Feb 200912:39 pmRNSR&D Pipeline Update
3rd Feb 200911:32 amRNSFurther re Agreement
2nd Dec 20087:00 amRNSInterim Results
3rd Oct 200810:47 amRNSHolding(s) in Company
2nd Oct 20083:17 pmRNSDirector/PDMR Shareholding
2nd Oct 200811:08 amRNSResult of AGM
1st Oct 20087:00 amRNSDirectorate Change
16th Sep 20083:22 pmRNSAdditional Listing
11th Sep 20089:49 amRNSAnnual Report and Accounts
2nd Sep 200811:44 amRNSHolding(s) in Company
1st Sep 20085:50 pmRNSGrant of options
1st Sep 200812:57 pmRNSDirectorate Change
29th Aug 20089:32 amRNSHolding(s) in Company
26th Aug 200810:41 amRNSResult of Meeting
21st Aug 20087:00 amRNSJoint Venture Project
4th Aug 20087:00 amRNSProvexis Fundraising
1st Aug 20084:32 pmRNSFinal Results
1st Aug 20084:30 pmRNSPlacing and Share Reorganisat
9th Jun 20084:52 pmRNSResponse to Share Price Movem
27th Mar 200810:07 amRNSHolding(s) in Company
20th Mar 20083:08 pmRNSHolding(s) in Company
3rd Mar 20089:51 amRNSHolding(s) in Company
25th Jan 200810:39 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.